Prognostic impact of 18F-FDG PET/CT in patients with multiple myeloma presenting with renal impairment

被引：0
作者：
Ahn, Seo-Yeon [1 ]
Park, Hwa Kyung [1 ]
Moon, Joon Ho [2 ]
Baek, Dong Won [2 ]
Cho, Hee-Jeong [2 ]
Sohn, Sang Kyun [2 ]
Kang, Sae-Ryung [3 ]
Min, Jung-Joon [3 ]
Bom, Hee-Seung [3 ]
Hong, Chae Moon [4 ]
Jeong, Shin Young [5 ]
Song, Ga-Young [1 ]
Yang, Deok-Hwan [1 ]
Ahn, Jae-Sook [1 ]
Kim, Hyeoung-Joon [1 ]
Jung, Sung-Hoon [1 ]
Lee, Je-Jung [1 ]
机构：
[1] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, 322 Seoyangro, Hwasun 519763, Jeollanamdo, South Korea
[2] Kyungpook Natl Univ Hosp, Dept Hematol Oncol, Daegu, South Korea
[3] Chonnam Natl Univ, Dept Nucl Med, Hwasun Hosp, 322 Seoyangro, Hwasun 519763, Jeollanamdo, South Korea
[4] Kyungpook Natl Univ Hosp, Dept Nucl Med, Daegu, South Korea
[5] Kyungpook Natl Univ, Dept Nucl Med, Chilgok Hosp, Daegu, South Korea
来源：
INTERNATIONAL JOURNAL OF HEMATOLOGY | 2021年 / 113卷 / 05期
关键词：
Multiple myeloma; Renal insufficiency; Positron emission tomography; Prognosis; INTERNATIONAL STAGING SYSTEM; POSITRON-EMISSION-TOMOGRAPHY; FDG PET/CT; FAILURE; STATEMENT; DIAGNOSIS; SURVIVAL; DIALYSIS; OUTCOMES; DISEASE;
D O I：
10.1007/s12185-021-03079-w
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Renal insufficiency (RI) is a frequent manifestation of multiple myeloma (MM) at time of diagnosis but there is no reliable prognostic factor for patients with MM presenting with RI. This study investigated the prognostic impact of F-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) in patients with MM with RI at diagnosis. The records of 209 patients with MM between June 2011 and November 2018 were retrospectively analyzed. PET/CT positivity was defined as the presence of more than three focal lesions or the presence of extramedullary disease. Of 209 patients, 90 (43.1%) had RI and showed similar survival outcomes to patients who had normal renal function. In total, 113 patients (54.0%) were PET/CT-positive, and 46.6% of patients with RI were PET/CT-positive at baseline. In patients with RI, those who were PET/CT-positive showed significantly inferior survival outcomes to those who were PET/CT-negative [progression-free survival (PFS), 12.7 vs. 34.0 months, P < 0.001; overall survival (OS), 42.2 months vs. not reached, P = 0.001]. On multivariate analysis, PET/CT positivity was significantly associated with PFS and OS in patients with RI. In conclusion, PET/CT is a reliable imaging technique for predicting survival outcomes in patients with MM with RI.
引用
收藏
页码：668 / 674
页数：7
相关论文
共 29 条
  • [1] 18F-FDG uptake and clearance in patients with compromised renal function
    Akers, Scott R.
    Werner, Thomas J.
    Rubello, Domenico
    Alavi, Abass
    Cheng, Gang
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (08) : 825 - 832
  • [2] Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party
    Augustson, BM
    Begum, G
    Dunn, JA
    Barth, NJ
    Davies, F
    Morgan, G
    Behrens, J
    Smith, A
    Child, JA
    Drayson, MT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) : 9219 - 9226
  • [3] F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
    Bartel, Twyla B.
    Haessler, Jeff
    Brown, Tracy L. Y.
    Shaughnessy, John D., Jr.
    van Rhee, Frits
    Anaissie, Elias
    Alpe, Terri
    Angtuaco, Edgardo
    Walker, Ronald
    Epstein, Joshua
    Crowley, John
    Barlogie, Bart
    [J]. BLOOD, 2009, 114 (10) : 2068 - 2076
  • [4] FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
    Boellaard, Ronald
    Delgado-Bolton, Roberto
    Oyen, Wim J. G.
    Giammarile, Francesco
    Tatsch, Klaus
    Eschner, Wolfgang
    Verzijlbergen, Fred J.
    Barrington, Sally F.
    Pike, Lucy C.
    Weber, Wolfgang A.
    Stroobants, Sigrid
    Delbeke, Dominique
    Donohoe, Kevin J.
    Holbrook, Scott
    Graham, Michael M.
    Testanera, Giorgio
    Hoekstra, Otto S.
    Zijlstra, Josee
    Visser, Eric
    Hoekstra, Corneline J.
    Pruim, Jan
    Willemsen, Antoon
    Arends, Bertjan
    Kotzerke, Joerg
    Bockisch, Andreas
    Beyer, Thomas
    Chiti, Arturo
    Krause, Bernd J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) : 328 - 354
  • [5] Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
    Cavo, Michele
    Terpos, Evangelos
    Nanni, Cristina
    Moreau, Philippe
    Lentzsch, Suzanne
    Zweegman, Sonja
    Hillengass, Jens
    Engelhardt, Monika
    Usmani, Saad Z.
    Vesole, David H.
    San-Miguel, Jesus
    Kumar, Shaji K.
    Richardson, Paul G.
    Mikhael, Joseph R.
    da Costa, Fernando Leal
    Dimopoulos, Meletios-Athanassios
    Zingaretti, Chiara
    Abildgaard, Niels
    Goldschmidt, Hartmut
    Orlowski, Robert Z.
    Chng, Wee Joo
    Einsele, Hermann
    Lonial, Sagar
    Barlogie, Bart
    Anderson, Kenneth C.
    Rajkumar, S. Vincent
    Durie, Brian G. M.
    Zamagni, Elena
    [J]. LANCET ONCOLOGY, 2017, 18 (04) : E206 - E217
  • [6] Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy
    Cho, Hyungwoo
    Yoon, Dok Hyun
    Lee, Jung Bok
    Kim, Sung-Yong
    Moon, Joon Ho
    Do, Young Rok
    Lee, Jae Hoon
    Park, Yong
    Lee, Ho Sup
    Eom, Hyeon Seok
    Shin, Ho-Jin
    Min, Chang-Ki
    Kim, Jin Seok
    Jo, Jae-Cheol
    Kang, Hye Jin
    Mun, Yeung-Chul
    Lee, Won Sik
    Lee, Je-Jung
    Suh, Cheolwon
    Kim, Kihyun
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) : 1280 - 1286
  • [7] Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities
    Davenport, Andrew
    Merlini, Giampaolo
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (10) : 3713 - 3718
  • [8] Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
    Dimopoulos, M. A.
    Roussou, M.
    Gavriatopoulou, M.
    Fotiou, D.
    Ziogas, D. C.
    Migkou, M.
    Panagiotidis, I.
    Eleutherakis-Papaiakovou, E.
    Kanellias, N.
    Psimenou, E.
    Marinaki, S.
    Bacharaki, D.
    Mparmparoussi, D.
    Matsouka, C.
    Giannouli, S.
    Terpos, E.
    Kastritis, E.
    [J]. BLOOD CANCER JOURNAL, 2017, 7 : e571 - e571
  • [9] Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents
    Dimopoulos, M. A.
    Delimpasi, S.
    Katodritou, E.
    Vassou, A.
    Kyrtsonis, M. C.
    Repousis, P.
    Kartasis, Z.
    Parcharidou, A.
    Michael, M.
    Michalis, E.
    Gika, D.
    Symeonidis, A.
    Pouli, A.
    Konstantopoulos, K.
    Terpos, E.
    Kastritis, E.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (01) : 195 - 200
  • [10] The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
    Dimopoulos, M. A.
    Roussou, M.
    Gkotzamanidou, M.
    Nikitas, N.
    Psimenou, E.
    Mparmparoussi, D.
    Matsouka, C.
    Spyropoulou-Vlachou, M.
    Terpos, E.
    Kastritis, E.
    [J]. LEUKEMIA, 2013, 27 (02) : 423 - 429
123